Site Editor
Soo Park, MD
Soo Park, MD
Posted: Monday, August 19, 2024
Hussein A. Tawbi, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues conducted the RELATIVITY-047 trial, which compared the combination of the monoclonal antibody relatlimab-rmbw and the PD-1 inhibitor nivolumab with nivolumab alone in patients with treatment-naive or unresectable melanoma. During the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9524), the investigators presented their updated descriptive analyses at the 3-year mark, since the combination has previously demonstrated a progression-free survival and overall survival benefit.
“Efficacy results also continued to favor nivolumab plus relatlimab vs nivolumab across the majority of prespecified subgroups,” concluded the study authors. “[The] safety of nivolumab plus relatlimab remained consistent with previous reports, with no new or unexpected safety signals.”
A total of 714 patients were randomly assigned on a 1:1 basis to receive 480 mg of nivolumab plus 160 mg of relatlimab (n = 355) in a fixed dose or 480 mg of nivolumab alone every 4 weeks (n = 359). Study endpoints included progression-free survival, overall survival, and objective response rate. Exploratory endpoints included efficacy of subsequent therapy, melanoma-specific survival, and central nervous system metastasis–free survival.
At the median follow-up of 33.8 months, nivolumab plus relatlimab continued to demonstrate a benefit in progression-free survival (hazard ratio [HR] = 0.79), overall survival (HR = 0.80), and melanoma-specific survival (HR = 0.75) compared with nivolumab alone; the objective response rate was also improved (43.7% vs 33.7%) .Of note, 141 patients given nivolumab monotherapy and 135 patients given nivolumab plus relatlimab received subsequent therapy.
Approximately 22% of patients who received combination therapy experienced grade 3 to 4 treatment-related adverse events compared with 12% of participants who received monotherapy. Furthermore, 18% of individuals given nivolumab plus relatlimab and 10% given nivolumab discontinued treatment because of these events. Furthermore, there were no new reports of treatment-related deaths since the last analysis.
Disclosure: For full disclosures of the study authors, visit coi.asco.org.
JNCCN Spotlights
